129 related articles for article (PubMed ID: 36091934)
21. Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up.
Soini EJO; Martikainen JA; Nousiainen T
Ann Oncol; 2011 May; 22(5):1189-1197. PubMed ID: 21135053
[TBL] [Abstract][Full Text] [Related]
22. R-CHOP compared to R-CHOP + X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Pasvolsky O; Rozental A; Raanani P; Gafter-Gvili A; Gurion R
Acta Oncol; 2021 Jun; 60(6):744-749. PubMed ID: 33734921
[TBL] [Abstract][Full Text] [Related]
23. A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation.
Liu X; Deng T; Guo X; Guo Y; Wang L; Zhang J; Xia Z; Zhang Q; Xue K; Cao J; Shi J; Hong X
Hematology; 2017 Jun; 22(5):258-264. PubMed ID: 27884092
[TBL] [Abstract][Full Text] [Related]
24. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
[TBL] [Abstract][Full Text] [Related]
25. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
[TBL] [Abstract][Full Text] [Related]
26. Clinical and histological features of primary testicular diffuse large B-cell lymphoma: a single center experience in China.
Zhou D; Bao C; Ye X; Zhu L; Zhu J; Li L; Zhu M; Yang X; Zheng Y; Huang X; Xie M; Xie W
Oncotarget; 2017 Dec; 8(68):112384-112389. PubMed ID: 29348832
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.
Castellino A; Chiappella A; LaPlant BR; Pederson LD; Gaidano G; Macon WR; Inghirami G; Reeder CB; Tucci A; King RL; Congiu A; Foran JM; Pavone V; Rivera CE; Spina M; Ansell SM; Cavallo F; Molinari AL; Ciccone G; Habermann TM; Witzig TE; Vitolo U; Nowakowski GS
Blood Cancer J; 2018 Nov; 8(11):108. PubMed ID: 30410035
[TBL] [Abstract][Full Text] [Related]
28. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
29. Prognostic nutritional index as a predictor of prognosis in patients with diffuse large B cell lymphoma.
Periša V; Zibar L; Knezović A; Periša I; Sinčić-Petričević J; Aurer I
Wien Klin Wochenschr; 2017 Jun; 129(11-12):411-419. PubMed ID: 27637206
[TBL] [Abstract][Full Text] [Related]
30. Extranodal site of diffuse large B-cell lymphoma and the risk of R-CHOP chemotherapy resistance and early relapse.
Ting CY; Gan GG; Bee-Lan Ong D; Tan SY; Bee PC
Int J Clin Pract; 2020 Oct; 74(10):e13594. PubMed ID: 32583545
[TBL] [Abstract][Full Text] [Related]
31. MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy.
Zhou M; Wang J; Ouyang J; Xu JY; Chen B; Zhang QG; Zhou RF; Yang YG; Shao XY; Xu Y; Chen YM; Fan XS; Wu HY
Tumour Biol; 2014 Jul; 35(7):6757-62. PubMed ID: 24719189
[TBL] [Abstract][Full Text] [Related]
32. Beclin1‑armed oncolytic Vaccinia virus enhances the therapeutic efficacy of R‑CHOP against lymphoma in vitro and in vivo.
Xie S; Fan W; Yang C; Lei W; Pan H; Tong X; Wu Y; Wang S
Oncol Rep; 2021 Mar; 45(3):987-996. PubMed ID: 33469679
[TBL] [Abstract][Full Text] [Related]
33. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma.
Lai GG; Lim ST; Tao M; Chan A; Li H; Quek R
Am J Hematol; 2009 Jul; 84(7):414-7. PubMed ID: 19415727
[TBL] [Abstract][Full Text] [Related]
34. [Interstitial pneumonia in patients with diffuse large B-cell lymphoma receiving RCHOP and RCDOP regimens].
Meng YN; Wang S; Shi Q; Xu PP; Cheng S; Wang L; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1015-1020. PubMed ID: 32023732
[No Abstract] [Full Text] [Related]
35. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Meng B; Zhang H
Hematol Oncol; 2019 Oct; 37(4):360-367. PubMed ID: 31359442
[TBL] [Abstract][Full Text] [Related]
36. [Current therapeutic strategies for diffuse large B‑cell lymphoma].
Pfreundschuh M
Internist (Berl); 2016 Mar; 57(3):214-21. PubMed ID: 26847364
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
Vitolo U; Chiappella A; Franceschetti S; Carella AM; Baldi I; Inghirami G; Spina M; Pavone V; Ladetto M; Liberati AM; Molinari AL; Zinzani P; Salvi F; Fattori PP; Zaccaria A; Dreyling M; Botto B; Castellino A; Congiu A; Gaudiano M; Zanni M; Ciccone G; Gaidano G; Rossi G;
Lancet Oncol; 2014 Jun; 15(7):730-7. PubMed ID: 24831981
[TBL] [Abstract][Full Text] [Related]
38. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
39. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
40. Prognostic values of various clinical factors and genetic subtypes for diffuse large B-cell lymphoma patients: a retrospective analysis of 227 cases.
Zhou D; Xie WZ; Hu KY; Huang WJ; Wei GQ; He JS; Shi JM; Luo Y; Li L; Zhu JJ; Zhang J; Lin MF; Ye XJ; Cai Z; Huang H
Asian Pac J Cancer Prev; 2013; 14(2):929-34. PubMed ID: 23621263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]